4 news items
Vir Biotechnology Appoints Mark Eisner, M.D., M.P.H. as Chief Medical Officer
VIR
29 May 24
visionary and enterprise mindset will be of great benefit to Vir as we focus on bringing medicine to patients with unmet medical needs
Multiple Abstracts Highlighting Vir Biotechnology's Latest Hepatitis Delta & B Data Accepted for Presentation at the EASL Congress 2024
VIR
22 May 24
Vir's strategy and plans, the potential clinical effects of tobevibart and elebsiran, the potential benefits, safety and efficacy of tobevibart
Vir Biotechnology Announces SOLSTICE Data to be Featured as an Oral Presentation at the European Association for the Study of the Liver (EASL) Congress 2024
VIR
21 May 24
and plans, the potential clinical effects of tobevibart and elebsiran, the potential benefits, safety and efficacy of tobevibart and elebsiran, the timing
Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule
VIR
5 Mar 24
regarding Vir's strategy and plans; the potential benefits, safety and efficacy of tobevibart and elebsiran for the treatment of chronic hepatitis delta
- Prev
- 1
- Next